SODIUM CHLORIDE (PISA)17.7 %/100ML INJ SOLUTION-I.V

Limited Stock

Category

Pharmaceuticals Supplies

Code

SODIUM CHLORIDE (PISA)17.7%/100

$10.87

Description

Address critical electrolyte deficiencies and acute water intoxication with Sodium Chloride 17.7% Injectable Solution. Manufactured by Laboratorios PiSA, this high-potency, hypertonic electrolyte solution contains $177 \text{ mg}$ of pure sodium chloride per milliliter.

Because of its heavy concentration, this preparation serves as a powerful additive for central intravenous infusion protocols. It is designed to restore structural fluid balance and correct severe, symptomatic sodium depletion under strict clinical supervision.

Key Features

  • High-Potency Hypertonic Fluid: Formulated at a concentrated 17.7% matrix ($17.7 \text{ g}$ per $100 \text{ mL}$), providing an immediate source of extracellular sodium and chloride ions to correct severe osmotic imbalances.

  • Rapid Correction of Severe Hyponatremia: Acts directly to elevate critically low blood sodium levels, helping to prevent or resolve life-threatening neurological complications like cerebral edema, severe headaches, or seizures.

  • Water Intoxication Therapy: Effectively treats relative hyponatremia caused by severe overhydration, accelerating the restoration of a healthy sodium-to-water ratio.

  • Flexible Infusion Compounding: Serves as a primary electrolyte concentrate that clinical personnel can easily introduce into standard, large-volume carrier bags (such as $5\%$ Dextrose or Normal Saline) to tailor exact therapeutic regimens.

  • Premium PiSA Quality Assurance: Manufactured under strict aseptic conditions to guarantee a sterile, non-pyrogenic fluid path.

Common Indications for Use

Sodium Chloride 17.7% is indicated across hospital settings for:

  • Severe, Symptomatic Hyponatremia: Immediate correction of critically low plasma sodium concentrations ($< 120 \text{ mEq/L}$) presenting with altered mental status or neurological distress.

  • Hypochloremic Alkalosis: Restoring essential chloride ions to treat severe metabolic alkalosis driven by prolonged vomiting or gastric suctioning.

  • Severe Salt Depletion: Replenishing massive sodium losses without overloading the patient with excess fluid volume.

Technical Specifications

Feature Specification
Brand Name / Line Solución CS-C / Electrolitos Concentrados
Active Ingredient Sodium Chloride (Cloruro de Sodio) 17.7%
Concentration Profile 17.7 g of NaCl per 100 mL ($177 \text{ mg/mL}$)
Format Concentrated Injectable Solution for Infusion
Manufacturer Laboratorios PiSA, S.A. de C.V.
Route of Administration Intravenous (I.V.) Perfuser Administration Only
Classification Hypertonic Electrolyte Replacement

Administration & Clinical Workflow Best Practices

CRITICAL CLINICAL WARNING (MUST BE DILUTED): Never administer this hypertonic solution directly via rapid, undiluted IV push. Direct, rapid injection of a 17.7% saline concentrate can cause severe localized venous thrombosis, chemical phlebitis, and life-threatening Central Pontine Myelinolysis (irreversible neurological damage caused by correcting sodium levels too rapidly).

  • Dilution Requirement: Must be added to a compatible large-volume parenteral fluid bag and mixed thoroughly before administration.

  • Regulated Rate: Administer slowly via an electronic infusion pump, closely monitoring serum electrolyte levels, fluid balance, and acid-base statuses every few hours.

  • Target Correction Speed: Standard clinical safety guidelines recommend raising serum sodium levels at a controlled rate, typically not exceeding $1 \text{ mEq/L}$ per hour or a total of $8 \text{ to } 10 \text{ mEq/L}$ within any 24-hour window.

Important Safety Warnings & Precautions

  • Contraindications: Do not administer to patients with hypernatremia, hyperchloremia, severe fluid retention (edema), unmanaged severe hypertension, advanced renal failure, or congestive heart failure (CHF) where sodium restriction is vital.

  • Corticosteroid Interreactions: Use with extreme caution in patients receiving corticosteroids or corticotropin, as these medications promote sodium retention and can exacerbate fluid overload.

  • Monitoring: Periodically check the injection site for signs of localized tissue irritation, inflammation, or extravasation.

Storage: Store at controlled room temperature not exceeding 30°C (86°F) in a dry environment. Do not freeze. Use immediately once open or compounded into a larger IV carrier bag; discard any unused portions safely. Keep out of reach of children.